US · PLRX · BIOTECHNOLOGY
Pliant Therapeutics, Inc. (PLRX) intrinsic value and stock valuation
$0.60as of 2026-11-21 · Mkt cap 65.02M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Pliant Therapeutics, Inc. DCF and intrinsic value
InvestorsCraft values PLRX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from PLRX’s statements →
Pliant Therapeutics, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2017–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $1.58M | $9.69M | $7.57M |
| Operating income | -$-150.07M | -$-228.37M | -$-184.15M | -$-127.2M | -$-97.53M |
| Net income | -$-149.34M | -$-210.3M | -$-161.34M | -$-123.32M | -$-97.26M |
| EPSd | -$-2.43M | -$-3.47M | -$-2.75M | -$-2.93M | -$-2.71M |
| Operating cash flow | -$-128.34M | -$-155.5M | -$-116.36M | -$-94.63M | -$-75.44M |
| Capital expenditure | -$-370K | -$-3.85M | -$-920K | -$-1.76M | -$-1.95M |
| Free cash flow | -$-128.71M | -$-159.35M | -$-117.28M | -$-96.39M | -$-77.4M |
| Total assets | $225.2M | $397M | $512.2M | $350.6M | $221.2M |
| Total debt | $29.1M | $60.2M | $11.4M | $15.8M | $7.19M |
| Net debt | -$-16.34M | -$-11M | -$-51.86M | -$-17.87M | -$-44.47M |
| Total equity | $181.2M | $304.1M | $473.6M | $313.3M | $199.1M |
| Cash and short-term investments | $190.9M | $355.7M | $494.3M | $331.2M | $200.6M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $1.58M | $9.69M | $7.57M |
| Cost of revenue | $1.7M | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | -$-1.7M | $0.00 | $1.58M | $9.69M | $7.57M |
| Research and development expenses | $109.2M | $169.3M | $127.8M | $96.9M | $77.6M |
| Selling, general and administrative expenses | $47.2M | $59.1M | $57.9M | $40M | $27.6M |
| Other expenses | -$-8M | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating expenses | $148.4M | $228.4M | $185.7M | $136.9M | $105.1M |
| Cost and expenses | $150.1M | $228.4M | $185.7M | $136.9M | $105.1M |
| Interest income | $0.00 | $21.1M | $24.1M | $4.67M | $270K |
| Interest expense | $2.56M | $3.02M | $1.27M | $790K | $0.00 |
| Depreciation and amortization | $1.7M | $2.12M | $1.84M | $3.68M | $1.53M |
| Ebitda | -$-145.09M | -$-205.16M | -$-158.23M | -$-118.85M | -$-95.73M |
| Operating income | -$-150.07M | -$-228.37M | -$-184.15M | -$-127.2M | -$-97.53M |
| Total other income/expenses, net | $730K | $18.1M | $22.8M | $3.88M | $270K |
| Income before tax | -$-149.34M | -$-210.3M | -$-161.34M | -$-123.32M | -$-97.26M |
| Income tax expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$-149.34M | -$-210.3M | -$-161.34M | -$-123.32M | -$-97.26M |
| Weighted average shares outstanding | $61.4M | $60.5M | $58.7M | $42M | $35.9M |
| Weighted average diluted shares outstanding | $61.4M | $60.5M | $58.7M | $42M | $35.9M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $190.9M | $355.7M | $494.3M | $331.2M | $200.6M |
| Net receivables | $820K | $2.3M | $3M | $3.14M | $2.47M |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current assets | $196.5M | $362.3M | $505.5M | $340.3M | $209.4M |
| Property, plant and equipment, net | $25M | $32.8M | $4.78M | $9.91M | $10.9M |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Long-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $28.8M | $34.7M | $6.65M | $10.3M | $11.8M |
| Total assets | $225.2M | $397M | $512.2M | $350.6M | $221.2M |
| Accounts payable | $480K | $5.96M | $4.53M | $1.58M | $2.97M |
| Short-term debt | $1.45M | $540K | $1.32M | $2.46M | $1.87M |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $16.4M | $33.2M | $28.5M | $23.9M | $16.8M |
| Long-term debt | $27.7M | $59.7M | $10.1M | $13.4M | $5.33M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $27.7M | $59.7M | $10.1M | $13.4M | $5.33M |
| Capital lease obligations | $29.1M | $30M | $1.32M | $5.89M | $7.19M |
| Total liabilities | $44M | $92.9M | $38.6M | $37.3M | $22.2M |
| Common stock | $10K | $10K | $10K | $10K | $0.00 |
| Retained earnings | -$-859.4M | -$-710.05M | -$-499.75M | -$-338.41M | -$-215.09M |
| Accumulated other comprehensive income (loss) | -$-10K | $320K | $340K | -$-1.96M | -$-200K |
| Total equity | $181.2M | $304.1M | $473.6M | $313.3M | $199.1M |
| Total investments | $145.5M | $284.5M | $431M | $297.5M | $148.9M |
| Total debt | $29.1M | $60.2M | $11.4M | $15.8M | $7.19M |
| Net debt | -$-16.34M | -$-11M | -$-51.86M | -$-17.87M | -$-44.47M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-149.34M | -$-210.3M | -$-161.34M | -$-123.32M | -$-97.26M |
| Depreciation and amortization | $1.7M | $2.12M | $1.84M | $1.82M | $1.53M |
| Stock-based compensation | $26.2M | $37.6M | $44.5M | $22.6M | $10.4M |
| Change in working capital | -$-15.94M | $9.09M | $1.25M | $4.22M | $6.92M |
| Accounts receivable | $0.00 | $0.00 | $1.98M | $10K | $7.28M |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Accounts payable | -$-5.48M | $1.43M | $2.97M | -$-1.35M | $890K |
| Net cash provided by operating activities | -$-128.34M | -$-155.5M | -$-116.36M | -$-94.63M | -$-75.44M |
| Investments in property, plant and equipment | -$-370K | -$-3.85M | -$-920K | -$-1.76M | -$-1.95M |
| Acquisitions, net | $150K | $0.00 | $0.00 | $148.4M | -$-75.65M |
| Net cash used for investing activities | $134.3M | $140.3M | -$-127.01M | -$-150.2M | $73.7M |
| Common stock issued | $570K | $3.21M | $275.3M | $215.6M | $2.98M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | -$-31.7M | $23.1M | $274.4M | $226.9M | $2.53M |
| Net change in cash | -$-25.74M | $7.95M | $31M | -$-17.98M | $780K |
| Cash at end of period | $46.9M | $72.7M | $64.7M | $33.7M | $51.7M |
| Operating cash flow | -$-128.34M | -$-155.5M | -$-116.36M | -$-94.63M | -$-75.44M |
| Capital expenditure | -$-370K | -$-3.85M | -$-920K | -$-1.76M | -$-1.95M |
| Free cash flow | -$-128.71M | -$-159.35M | -$-117.28M | -$-96.39M | -$-77.4M |
Line items
Line items
Line items
About Pliant Therapeutics, Inc.
Pliant Therapeutics, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to discovering, advancing, and bringing to market innovative therapies for fibrotic and related diseases across the United States. Its flagship investigational product, PLN-74809, is an orally administered, small-molecule, dual-selective inhibitor targeting both avß6 and avß1 integrins, which is currently progressing through three distinct Phase 2a clinical trials. The company's pipeline also includes PLN-1474, a small-molecule selective inhibitor of avß1, which has successfully completed its Phase 1 clinical assessment for treating liver fibrosis associated with nonalcoholic steatohepatitis (NASH). Furthermore, Pliant is nurturing two additional integrin-based initiatives in preclinical development: one focused on oncology, and another involving an allosteric agonistic monoclonal antibody designed to act upon an undisclosed integrin receptor for the treatment of various muscular dystrophies, including Duchenne muscular dystrophy. Founded in 2015, Pliant Therapeutics, Inc. maintains its corporate headquarters in South San Francisco, California.
- CEO
- Bernard Coulie
- Employees
- 49
- Beta
- 1.22
Explore
Frequently asked questions
What is the intrinsic value of Pliant Therapeutics, Inc. (PLRX)?
InvestorsCraft does not currently publish an intrinsic value for PLRX. How the IC value is calculated.
Is PLRX undervalued?
InvestorsCraft does not publish an undervaluation signal for PLRX at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.